Check Cap Ltd (NASDAQ:CHEK) has earned a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy recommendation.
Analysts have set a 1 year consensus target price of $8.38 for the company and are anticipating that the company will post ($0.53) EPS for the current quarter, according to Zacks. Zacks has also given Check Cap an industry rank of 121 out of 255 based on the ratings given to related companies.
Several equities research analysts recently issued reports on the company. HC Wainwright reiterated a “buy” rating and issued a $14.00 price objective on shares of Check Cap in a report on Wednesday, May 23rd. Zacks Investment Research upgraded Check Cap from a “hold” rating to a “buy” rating and set a $5.00 price objective on the stock in a report on Wednesday, May 9th.
Check Cap (NASDAQ:CHEK) last issued its quarterly earnings results on Friday, August 10th. The medical research company reported ($0.70) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.82) by $0.12. analysts anticipate that Check Cap will post -2.6 EPS for the current fiscal year.
Check Cap Company Profile
Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based system that utilizes low-dose X-rays for screening of the colon to detect polyps, masses, and colorectal cancers in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a biocompatible unit worn on the patient's back for capsule control, tracking, and data recording; and C-Scan View, a personal computer-based software package, which is designed to retrieve and process clinical data from the C-Scan Track, and to reconstruct and produce 3D visualization of the colon's inner surface.
Recommended Story: Book Value Of Equity Per Share – BVPS Explained
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Check Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check Cap and related companies with MarketBeat.com's FREE daily email newsletter.